Last updated: February 24, 2026
What is the Drug NDC 33342-0248?
The National Drug Code (NDC) 33342-0248 refers to a specific pharmaceutical product. The manufacturer is Teva Pharmaceuticals USA, Inc., and the drug is indicated for treatment of asthma and chronic obstructive pulmonary disease (COPD), marketed as QVAR RediHaler.
It is an inhalation corticosteroid (ICS) used for maintenance therapy in asthma management. The product formulation is 40 mcg per inhalation, delivered via the RediHaler device.
Market Size and Demand
Current Market Landscape
- The U.S. asthma population exceeds 25 million individuals.
- COPD affects over 16 million people in the U.S., with many also requiring ICS therapy.
- The inhaled corticosteroid market was valued at approximately $4.8 billion in 2022 (IQVIA).
- QVAR RediHaler holds an estimated 8% share of the inhaled corticosteroid segment within prescription asthma drugs.
Growth Drivers
- Rising prevalence of asthma and COPD.
- Shift towards eco-friendly inhaler devices with dosing safety features.
- Increased adoption of inhalers over nebulizers for maintenance therapy.
Competitive Products
| Product Name |
Formulation |
Market Share (%) |
Annual Sales (2022) |
Manufacturer |
| Symbicort |
ICS/LABA |
25 |
$1.2 billion |
AstraZeneca |
| Flovent |
ICS |
18 |
$900 million |
GlaxoSmithKline |
| QVAR RediHaler |
ICS (40 mcg) |
8 |
Estimated $150 million |
Teva |
Price Behavior Analysis
Historical Pricing Trends
- The average wholesale acquisition cost (WAC) for QVAR RediHaler in 2022 was approximately $150 per inhaler.
- Since FDA approval in 2020, prices have stabilized around this range, reflecting competition and manufacturing costs.
Pricing Dynamics
- Brand-name inhalers like QVAR RediHaler face pressure from generics and biosimilars.
- The entry of authorized generics typically reduces prices by 15-25%.
- Contractual discounting with payers and pharmacy benefit managers (PBMs) can lower net prices by 30-50%.
Projected Price Trends (Next 3-5 Years)
| Year |
Estimated WAC Price per Inhaler |
Notes |
| 2023 |
$150 |
Stable, slight discounts possible. |
| 2024 |
$145 |
Competition effects slightly reducing prices. |
| 2025 |
$140 |
Increased generic penetration anticipated. |
| 2026 |
$135 |
Price reduction driven by biosimilar/biosimilar entry. |
Key Factors Influencing Pricing
- Generic Competition: FDA approval of authorized generics expected by 2024.
- Policy Changes: Potential drug pricing reforms could influence net prices.
- Supply Chain: Manufacturing costs remain stable; shortages unlikely due to high demand.
Market Entry and Investment Considerations
- The inhaler segment remains resilient with high prescription volumes.
- Price reductions could impact profit margins but are offset by volume growth.
- Market expansion into Canada and Europe is constrained by regulatory pathways, but U.S. sales dominate.
Summary
The market for NDC 33342-0248 (QVAR RediHaler) is characterized by stable demand driven by asthma and COPD prevalence. The current price point is approximately $150 per inhaler, with a trend toward gradual decline over the next five years due to generic competition and market saturation. The overall market environment remains favorable for sustained sales, provided the patent exclusivity and market share are maintained.
Key Takeaways
- QVAR RediHaler commands roughly $150 per inhaler, with modest price erosion expected.
- Demand is driven by the large asthma and COPD patient populations.
- Competition from generics could reduce prices by up to 25% within five years.
- The inhaled corticosteroid market remains stable, with consistent growth prospects.
- Market expansion outside the U.S. faces regulatory hurdles but could provide additional revenue streams.
FAQs
1. How soon will generic versions of QVAR RediHaler enter the market?
Anticipated approval of authorized generics by 2024 could lead to price reductions and increased competition.
2. What is the potential impact of biosimilars or alternative inhaler devices?
Biosimilars and device innovations may pressure prices further, especially if they improve user convenience or reduce costs.
3. Are there supply chain risks affecting the product’s market?
No significant supply issues are projected given high demand and established manufacturing capabilities.
4. How does insurance coverage affect pricing and access?
Rebates, discounts, and formulary placement influence net prices and patient access, with bidirectional effects.
5. What are the regulatory challenges for expanding this drug’s market outside the U.S.?
Different approval processes, labeling requirements, and reimbursement policies complicate international expansion.
References
- IQVIA. (2022). Pharmaceutical Market Data.
- FDA. (2020). FDA Approval Notices.
- IMS Health. (2022). Inhaled Corticosteroid Market Analysis.
- Teva Pharmaceuticals. (2022). Product Portfolio and Market Reports.
- Centers for Disease Control and Prevention. (2022). Asthma Data and Statistics.
